PDF(Pubmed)
Abstract：
A randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the efficacy of infliximab, abatacept, and cenicriviroc in treating patients hospitalized with COVID-19. The patient\'s clinical status was assessed daily on an 8-point ordinal scale. We evaluated the totality of evidence on the efficacy of the 3 immunomodulators by considering all possible changes in the clinical status of each patient over time. We demonstrated that infliximab accelerated improvement and reduced deterioration of clinical status when added to standard of care. There was also evidence for the benefit of abatacept. There was no evidence for the benefit of cenicriviroc.
摘要：
一个随机的，双盲,进行安慰剂对照临床试验以研究英夫利昔单抗的疗效，abatacept,和cenicriviroc治疗COVID-19住院患者。患者的临床状态每天以8点序数量表进行评估。通过考虑每位患者临床状态随时间的所有可能变化，我们评估了3种免疫调节剂功效的全部证据。我们证明，英夫利昔单抗在加入标准治疗时加速了临床状态的改善并减少了临床状态的恶化。也有证据表明abatacept的好处。没有证据表明cenicriviroc有好处。
